These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings
1. Regeneron reported Q2 earnings of $12.89 per share, beating expectations. 2. Sales reached $3.68 billion, exceeding estimates of $3.29 billion. 3. Gross margin outlook for 2025 adjusted down slightly to 83% from 84%. 4. Significant sales growth driven by EYLEA HD, Dupixent, and Libtayo. 5. Analysts raised price targets post-earnings, showing continued confidence in REGN.